New Starts of Psychotropic Medications Dropped During COVID-19

New starts of antidepressants declined by 7.5%, anxiolytics by 5.6%, and antipsychotics by 2.6% compared with forecast levels during the first five months of the COVID-19 pandemic, according to a new study published in Health Affairs. For all medications, declines in new starts were particularly dramatic during the initial stay-at-home order period from March to May 2020. Though there was a significant rebound in new prescription starts after mid-May, the numbers remained below 2019 levels. There were substantial drops in new starts for patients younger than 18, across all medication classes, with a 34.6% decline in antidepressants, 27.3% in anxiolytics and 22.2% in antipsychotics compared with the expected levels.

© 2022 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

pills
September 22

Report Shows Limited Access to Opioid Use Disorder Treatments for Medicare Beneficiaries

READ MORE
cms-website
September 22

Drug Price Negotiation Will Require New CMS Regulations, Staffing

READ MORE
fda-sign
September 22

Accelerated Approval Prices Are Unrelated to Clinical Value, Study Says

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today